Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
| Autor: | Adrienne Morey, Sayed Ali, Desmond Yip, Gregory Gaughran, Christine Archer, Manreet Randhawa, Paul Pavli |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
musculoskeletal diseases
0301 basic medicine Oncology medicine.medical_specialty Metastatic melanoma Ipilimumab Vedolizumab 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine Case report Medicine Steroid-refractory colitis Colitis skin and connective tissue diseases Infliximab-refractory colitis business.industry biochemical phenomena metabolism and nutrition medicine.disease Infliximab Immune checkpoint stomatognathic diseases Nivolumab 030104 developmental biology 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | World Journal of Clinical Oncology |
| ISSN: | 2218-4333 |
| Popis: | BACKGROUND Dual checkpoint inhibition improves response rates in treatment naïve patients with metastatic melanoma compared to monotherapy. However, it confers a higher rate of toxicity, including immune-related colitis. Steroids may not resolve symptoms in all cases. The use of vedolizumab, a humanized monoclonal antibody against α4β7 integrin has proven effective in cases refractory to standard treatment. CASE SUMMARY We report the case of a 27-year-old female with Stage IVd metastatic melanoma treated with ipilimumab and nivolumab. She developed severe colitis refractory to methylprednisolone, infliximab and mycophenolate mofetil but responded to vedolizumab. CONCLUSION This case report supports vedolizumab use in severe immune related colitis refractory to standard immunosuppression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|